搜索结果


   AKR1A1

靶点ID:TCMBANKGE006907


靶点别名:ALDR1; ALR; ARM; DD3; HEL-S-6


靶点描述:aldo-keto reductase family 1 member A1


染色体:1


染色体位置:1p34.1


靶点类型:protein-coding


HERB_ID:-


HGNC_Link:380


OMIM_Link:103830


Ensembl_Link:ENSG00000117448


   靶点对应的植物
ID 拉丁名 药名 药用植物名 功能与主治 来源 药用部位 使用民族

   靶点对应的化合物
化合物ID 化合物名 别名 分子式 分子质量 Smiles
TCMBANKIN006447 Xanthomicrol NCGC00169227-01; 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxychromen-4-one; NSC 79323; CTK4D2076; LMPK12111447; AIDS-071758; 3IN82Y8CAA; 4H-1-Benzopyran-4-one,5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-; CHEBI:35047; BDBM50412279; 5-Hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-4H-1-benzopyran-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-chromone; AC1Q6AJ4; 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-4H-chromen-4-one; SCHEMBL6257160; AIDS071758; 4',5-dihydroxy-6,7,8-trimethoxyflavone; 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-chromen-4-one; 16545-23-6; C14476; xanthomicrol; CHEMBL476121; UNII-3IN82Y8CAA; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-; 5-hydroxy-2-(4-hydroxyphenyl)-6,7,8-trimethoxy-4-chromenone; AK544883; LS-193898; DTXSID20167947; NSC79323; BRD-K34022850-001-01-8; AC1L2JGB; AKOS030525194; ACon1_000922 C18H16O7 344.32 COC1=C(C(=C2C(=C1O)C(=O)C=C(O2)C3=CC=C(C=C3)O)OC)OC
TCMBANKIN018594 dicaffeoylquinic acid C25H24O12 516.4 g/mol C1C(C(C(CC1(C(=O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O)OC(=O)C=CC3=CC(=C(C=C3)O)O
TCMBANKIN025923 cirsiliol 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxychromen-4-one; 6,7-Dimethoxy-5,3',4'-trihydroxyflavone; AKOS025287589; 3',4',5-trihydoxy-6,7-dimethoxyflavone; CTK8I3082; 3',4',5-Trihydroxy-6,7-dimethoxyflavone; ST50331608; LS-193892; BDBM50025321; DTXSID60187907; AC1L4N9W; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-; 5,3'',4''-Trihydroxy-6,7-dimethoxyflavone; CHEMBL72637; AC1Q6AIE; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4H-1-benzopyran-4-one; 5,3',4'-trihydroxy-6,7-dimethoxyflavone; 34334-69-5; C10033; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-chromone; ZINC4098510; MCULE-9854332110; 2-(3,4-Dihydroxy-phenyl)-5-hydroxy-6,7-dimethoxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4H-chromen-4-one; MFCD00210577; ST5331608; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4-chromenone; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-chromen-4-one; MolPort-009-754-980; CHEBI:3719; FT-0620861; 6-methoxyluteolin 7-methyl ether; LMPK12111227; SCHEMBL1614677; Cirsiliol; 3',4',5-TRIHYDROXY-6,7-DIMETHOXY FLAVONE C17H14O7 330.29 g/mol COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)OC
TCMBANKIN033702 citric acid InChI=1/C6H8O7/c7-3(8)1-6(13,5(11)12)2-4(9)10/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12; NCGC00090954-02; NCGC00090954-01; HSDB 911; CIT; Citric acid (8CI); BRN 0782061; NCIStruc2_000099; 27109_RIEDEL; AIDS-017733; 1,2,3-PROPANETRICARBOXYLIC ACID,2-HYDROXY (CITRIC ACID); citr; 27488_FLUKA; FEMA No. 2306; E 330; 27485_FLUKA; 27487_FLUKA; 77-92-9; C2404_SIGMA; 2-Hydroxytricarballylic acid; NCIOpen2_004502; F 0001 (polycarboxylic acid); EPA Pesticide Chemical Code 021801; AI3-06286; 245654-34-6; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-; Citretten; Kyselina citronova; 2-hydroxypropane-1,2,3-tricarboxylic acid; Anhydrous citric acid; Citrate standard for IC; C83155_SIAL; LS-2418; WLN: QV1XQVQ1VQ; 1,2,3-Propanetricarboxylic acid, 2-hydroxy- (9CI); NSC30279; .beta.-Hydroxytricarballylic acid; NSC 626579; FLC; NCI60_022579; LS-3185; 2-hydroxy-1,2,3-propanetricarboxylic acid; Caswell No. 221C; EINECS 201-069-1; 43136-35-2; 251275_SIAL; 38730_FLUKA; C4540_SIGMA; FEMA Number 2306; 4-03-00-01272 (Beilstein Handbook Reference); 3-Carboxy-3-hydroxypentane-1,5-dioic acid; Citric acid anhydrous (JAN); C00158; 12262-73-6; 240621_ALDRICH; AIDS017733; MLS001066346; Kyselina 2-hydroxy-1,2,3-propantrikarbonova [Czech]; 2-Hydroxypropanetricarboxylic acid; CCRIS 3292; KBio3_002740; NSC626579; D00037; SBB008922; Kyselina citronova [Czech]; Aciletten; NSC 30279; Anhydrous citric acid (JP15); 46933_SUPELCO; NCIOpen2_004062; Citric acid solution; CHEBI:30769; Citro; BSPBio_003240; NCIStruc1_000057; Uro-trainer; Citric acid, anhydrous (USP); W230618_ALDRICH; Citric acid [USAN:JAN]; H3cit; Chemfill; Hydrocerol A; Suby G; Oprea1_502996; Citric acid, anhydrous; SMR000471840; Citric acid anhydrous; Spectrum3_001850 C6H8O7 192.12 C(C(=O)O)C(CC(=O)O)(C(=O)O)O
TCMBANKIN058174 2,4,2',4'-tetrahydroxychalcone C15H12O5 272.25 g/mol C1=CC(=C(C=C1O)O)C=CC(=O)C2=C(C=C(C=C2)O)O
TCMBANKIN058192 isoliquiritigenin HCC; KBio2_000625; SPBio_000949; Spectrum2_000875; 961-29-5; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; SPECTRUM1504200; Chalcone, 2',4,4'-trihydroxy-; CHEMBL1395334; KBio3_002631; NCGC00015556-01; SDCCGMLS-0066751.P001; ST5309279; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; KBio2_003193; InChI=1/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; CMLD3_000056; BSPBio_003411; C08650; CCRIS 7676; 2',4,4'-Trihydroxychalcone; Lopac0_000681; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; I159_SIGMA; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; Lopac-I-3766; CPD-3041; KBio1_001802; MEGxp0_001326; ZINC3869607; BRN 1914295; MLS000438943; SMR000112969; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; ACon1_000047; GU 17; KBioGR_002232; DivK1c_006858; KBio2_005761; 1-08-00-00707 (Beilstein Handbook Reference); 4,2′,4′-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; NCGC00090504-01; (Z)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; EU-0100681; Spectrum3_001656; AC1O7G44; 4,2',4'-Trihydroxychalcone; EINECS 237-316-5; I3766_SIGMA; AIDS035379; AIDS-035379; 13745-20-5; Spectrum5_000612; 2-propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; Spectrum_000145; KBioSS_000625; Isoliquiritigenin; Spectrum4_001756; 42'4'-trihydroxychalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; NCGC00090504-03; SpecPlus_000762; 2',4',4-trihydroxychalcone C15H12O4 256.25 g/mol C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O
TCMBANKIN058213 kaemferol;kampferol;kaempferol;campherol TNP00039; nchembio.2007.28-comp30; Kaempherol; 5-18-05-00251 (Beilstein Handbook Reference); Prestwick2_001098; CHEBI:28499; Prestwick1_001098; CAS-520-18-3; BRN 0304401; Flavone, 3,4',5,7-tetrahydroxy-; ST030560; MEGxp0_001283; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; C.I. 75640; Swartziol; K0133_SIGMA; kaempferol oxoanion; NCGC00016480-01; 60010_FLUKA; EINECS 208-287-6; Pelargidenon; Nimbecetin; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4-chromenone; NSC 407289; 3,4',5,7-Tetrahydroxyflavone; HSCI1_000027; Pelargidenolon 1497; NSC407289; Robigenin; C05903; CPD1F-90; Kampferol; NSC 656277; Prestwick0_001098; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Populnetin; Kampcetin; Prestwick3_001098; AIDS-001404; ZINC00137345; kaempferol ; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-olate; 3,4′,5,7-Tetrahydroxyflavone; Rhamnolutein; NCGC00016480-02; ACon1_001867; NSC656277; 3,4′,5,7-Tetrahydroxyflavone; BSPBio_001176; SPBio_003058; Oprea1_650954; 5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); Campherol; 520-18-3; 3,5,7-TRIHYDROXY-2-(4-HYDROXYPHENYL)-4H-CHROMEN-4-ONE; S00111; Trifolitin; Kampherol; AI3-36096; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromone; Indigo yellow; Pelargidenolon; AIDS001404; nchembio718-comp14; NCGC00091036-01; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); CHEBI:58573; Kaemferol; Kempferol; BPBio1_001294; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Rhamnolutin; 3,5,7-triOH-Flavone; KMP; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- C15H10O6 286.24 g/mol C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O
TCMBANKIN058376 indole-3-acetalbehyde C10H9NO C1=CC=C2C(=C1)C(=CN2)CC=O
TCMBANKIN058378 IEA beta-Indol-3-ylethanol; NSC3884; NSC 3884; 3-Indolylethanol; 3-(beta-Hydroxyethyl)indole; Maybridge1_002422; BRN 0125553; Indole-3-ethanol; 3-(2-Hydroxyethyl)indole; 2-(3-Indolyl)ethanol; Ethanol, 3-indolyl-; CHEBI:17890; Indole ethanol; Indoleethanol; T90301_ALDRICH; EINECS 208-393-2; WLN: T56 BMJ D2Q; 5-21-03-00061 (Beilstein Handbook Reference); SBB003950; CDS1_000134; 1H-indolyl-3-ethanol; DivK1c_001174; Tryptophol; 2-(indol-3-yl)ethanol; 526-55-6; 1H-Indole-3-ethanol; Ethanol, 2-indol-3-yl-; .beta.-(3-Indole)ethanol; 3-Indoleethanol; ZINC00003252; C00955; 3-(.beta.-Hydroxyethyl)indole; Indole-3-ethanol (8CI); 54350_FLUKA; 2-(1H-indol-3-yl)ethanol C10H11NO 161.2 g/mol C1=CC=C2C(=C1)C(=CN2)CCO
TCMBANKIN058908 Butanedione diacetyl; 2,3-Butanedione; biacetyl; 2,3-Butadione; 2,3-diketobutane; dimethylglyoxal; WLN: 1VV1; 4-01-00-03644 (Beilstein Handbook Reference); EU-0100387; Diacetyl (natural); NSC8750; W237035_ALDRICH; 2,3-Butanedione (8CI,9CI); Butanedione; 2,3-butanedione; UN2346; SGCUT00113; InChI=1/C4H6O2/c1-3(5)4(2)6/h1-2H; Lopac-D-3634; 11038_FLUKA; CCRIS 827; EINECS 207-069-8; dimethyl diketone; ZINC01532732; 151677-70-2; to_000005; 625-34-3; Butanal, 3-oxo-; FEMA No. 2370; NCGC00015336-01; DIACETYL; Butane-2,3-dione; CHEBI:16583; NSC 8750; Butanedione [UN2346] [Flammable liquid]; LS-116; W237000_ALDRICH; 31530_FLUKA; Lopac0_000387; Butanedione [UN2346] [Flammable liquid]; BRN 0605398; 2,3-dioxobutane; butadione; 431-03-8; C00741; NCGC00090746-01; AI3-03313; 2,3-butandione; HSDB 297; Acetoacetaldehyde; B85307_ALDRICH; Dimethyl glyoxal; Glyoxal, dimethyl- CH3COCOCH3 86.09 g/mol CC(=O)C(=O)C
TCMBANKIN059452 ethyl aldehyde C2H4O 44.05 g/mol CC=O
TCMBANKIN059814 tanshinone vi C18H16O4 296.3 g/mol CC1=C2C=CC3=C(C2=CC=C1)C(=O)C(=O)C(=C3O)C(C)CO
TCMBANKIN060615 dihydrotanshinone i C18H14O3 278.3 g/mol CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C
TCMBANKIN060616 dihydrotanshinoneⅠ C18H14O3 45.043279 CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3C=CC=C4C
TCMBANKIN061202 Butanol C4H10O 74.12 g/mol CCCCO
TCMBANKIN061444 Pedalitin 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-methoxy-; FLAVONE, 3',4',5,6-TETRAHYDROXY-7-METHOXY-; 5,6,3',4'-Tetrahydroxy-7-methoxyflavone; BRN 1296526; 3',4',5,6-Tetrahydroxy-7-methoxyflavone; pedalitin; 2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-methoxy-4-chromenone; 22384-63-0; 5-18-05-00543 (Beilstein Handbook Reference); C10119; 2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-methoxychromen-4-one; 2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-methoxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,6-dihydroxy-7-methoxy-chromone; 5,6,3',4'-tetrahydroxy-7-methoxyflavone C16H12O7 316.26 COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)O
TCMBANKIN061445 cirsiliol 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxychromen-4-one; 6,7-Dimethoxy-5,3',4'-trihydroxyflavone; AKOS025287589; 3',4',5-trihydoxy-6,7-dimethoxyflavone; CTK8I3082; 3',4',5-Trihydroxy-6,7-dimethoxyflavone; ST50331608; LS-193892; BDBM50025321; DTXSID60187907; AC1L4N9W; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-; 5,3'',4''-Trihydroxy-6,7-dimethoxyflavone; CHEMBL72637; AC1Q6AIE; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4H-1-benzopyran-4-one; 5,3',4'-trihydroxy-6,7-dimethoxyflavone; 34334-69-5; C10033; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-chromone; ZINC4098510; MCULE-9854332110; 2-(3,4-Dihydroxy-phenyl)-5-hydroxy-6,7-dimethoxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4H-chromen-4-one; MFCD00210577; ST5331608; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-4-chromenone; 2-(3,4-dihydroxyphenyl)-5-hydroxy-6,7-dimethoxy-chromen-4-one; MolPort-009-754-980; CHEBI:3719; FT-0620861; 6-methoxyluteolin 7-methyl ether; LMPK12111227; SCHEMBL1614677; Cirsiliol; 3',4',5-TRIHYDROXY-6,7-DIMETHOXY FLAVONE; 5,3′,4′-trihydroxy-6,7-dimethoxyflavone C17H14O7 330.29 g/mol COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC(=C(C=C3)O)O)O)OC
TCMBANKIN061447 cirsimaritin Skrofulein;7-Methylcapillarisin;C17785; MolPort-000-779-119; 6601-62-3; W1605; Flavone, 4',5-dihydroxy-6,7-dimethoxy-; cirsimaritin ; DTXSID00216220; 5-Hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-4H-chromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-chromen-4-one; 5,4''-Dihydroxy-6,7-dimethoxyflavone; SMR000440660; AC1L4MLD; AC1Q6AIG; D06NRZ; Cirsimaritin; 4CN-1595; CHEMBL348436; 6-Methoxygenkwanin; CTK2F4258; CHEBI:81337; LMPK12111163; Skrofulein; AKOS030556306; NCGC00169297-01; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-4H-1-benzopyran-4-one; cirsimartin; 5-Hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-4H-chromen-4-one #; SCHEMBL1663486; cid_188323; ZINC1081537; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-; NP-001331; 4',5-Dihydroxy-6,7-dimethoxyflavone; BRD-K58305393-001-01-2; PubChem SID: 26725076; MEGxp0_000498; 5-Hydroxy-2-(4-hydroxy-phenyl)-6,7-dimethoxy-chromen-4-one; 6,7-Dimethoxyscutellarein; ZIIAJIWLQUVGHB-UHFFFAOYSA-N; MCULE-1790924522; ACon1_000850; AK587011; Scrophulein; BDBM50049394; HMS2271M05; Cirsimaritin, >=90% (LC/MS-ELSD); 7-Methylcapillarisin; LS-193899; MLS000876998;5-hydroxy-2-(4-hydroxyphenoxy)-6,7-dimethoxy-chromen-4-one; 7-methylcapillarisin; 5-hydroxy-2-(4-hydroxyphenoxy)-6,7-dimethoxy-4-chromenone; 5-hydroxy-2-(4-hydroxyphenoxy)-6,7-dimethoxychromen-4-one; 5-hydroxy-2-(4-hydroxyphenoxy)-6,7-dimethoxy-chromone;MLS000876998; 6601-62-3; Cirsimaritin; MEGxp0_000498; Flavone, 4',5-dihydroxy-6,7-dimethoxy-; ACon1_000850; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-chromone; SMR000440660; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxychromen-4-one; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-chromen-4-one; ZINC01081537; 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy-4-chromenone; 4',5-Dihydroxy-6,7-dimethoxyflavone; 4H-1-Benzopyran-4-one, 5-hydroxy-2-(4-hydroxyphenyl)-6,7-dimethoxy- C17H14O6 314.29 g/mol COC1=C(C(=C2C(=C1)OC(=CC2=O)C3=CC=C(C=C3)O)O)OC
TCMBANKIN061450 sideritiflavone C18H16O8 360.3 g/mol COC1=C(C(=C2C(=C1O)C(=O)C=C(O2)C3=CC(=C(C=C3)O)O)OC)OC
TCMBANKIN061663 axillarin 3',4',5,7-Tetrahydroxy-3,6-dimethoxyflavone; axillarin ; DTXSID80199840; NCGC00168986-01; C10021; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-; CHEBI:2941; DMQT; Axillarin; 3',4',5,7-tetrahydroxy-3,6-dimethoxy-flavone; MCULE-1507651933; MEGxp0_000118; CHEMBL487810; AC1NQYPJ; 5188-73-8; 3,6-Dimethoxy-5,7,3',4'-tetrahydroxyflavone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxychromen-4-one; BDBM50242286; 3,6-Dimethoxyquercetagetin; ACon1_000535; SCHEMBL1155670; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-4H-chromen-4-one; Quercetagetin 3,6-dimethyl ether; NCGC00168986-02!2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxychromen-4-one; NP-000321; LMPK12112990; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-4H-1-benzopyran-4-one;ACon1_000535; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-chromone; 5188-73-8; 3',4',5,7-Tetrahydroxy-3,6-dimethoxyflavone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxychromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-; Quercetagetin 3,6-dimethyl ether; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,6-dimethoxy-4-chromenone; Axillarin; C10021; 3,6-Dimethoxyquercetagetin; MEGxp0_000118; DMQT C17H14O8 346.3 g/mol COC1=C(C2=C(C=C1O)OC(=C(C2=O)OC)C3=CC(=C(C=C3)O)O)O

   靶点对应的疾病
疾病ID 疾病名 MeSH名 HPO名 UMLS名 疾病类型
TCMBANKDI000054 Nervous System Diseases; Mental Disorders Abnormality of the nervous system Disease or Syndrome disease
TCMBANKDI000061 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process group
TCMBANKDI000076 Neoplasms - Neoplastic Process group
TCMBANKDI000166 - - Neoplastic Process disease
TCMBANKDI002165 Male Urogenital Diseases; Endocrine System Diseases Abnormality of the genitourinary system Disease or Syndrome disease
TCMBANKDI003248 Nutritional and Metabolic Diseases; Endocrine System Diseases Abnormality of metabolism/homeostasis; Abnormality of the endocrine system Disease or Syndrome disease
TCMBANKDI003353 Pathological Conditions, Signs and Symptoms; Neoplasms - Neoplastic Process phenotype
TCMBANKDI006337 Neoplasms - Neoplastic Process disease
TCMBANKDI007625 Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Chemically-Induced Disorders - Disease or Syndrome disease
TCMBANKDI008172 - - Mental or Behavioral Dysfunction disease
TCMBANKDI009912 Pathological Conditions, Signs and Symptoms Abnormality of metabolism/homeostasis Sign or Symptom phenotype
TCMBANKDI009951 Nutritional and Metabolic Diseases; Musculoskeletal Diseases Abnormality of the skeletal system Disease or Syndrome disease
TCMBANKDI010233 Musculoskeletal Diseases - Acquired Abnormality disease
TCMBANKDI011173 Neoplasms - Neoplastic Process disease
TCMBANKDI011393 Digestive System Diseases - Disease or Syndrome disease
TCMBANKDI011695 Neoplasms; Stomatognathic Diseases; Otorhinolaryngologic Diseases - Neoplastic Process disease
TCMBANKDI011776 Digestive System Diseases Abnormality of the digestive system; Constitutional symptom Disease or Syndrome disease
TCMBANKDI012178 Neoplasms - Neoplastic Process disease
TCMBANKDI012976 Neoplasms; Stomatognathic Diseases - Neoplastic Process disease
TCMBANKDI013628 Neoplasms; Skin and Connective Tissue Diseases - Neoplastic Process disease
TCMBANKDI015336 - - Disease or Syndrome phenotype
TCMBANKDI015485 Mental Disorders Abnormality of the nervous system Mental or Behavioral Dysfunction disease
TCMBANKDI015757 Infections - Disease or Syndrome disease
TCMBANKDI016890 Digestive System Diseases; Neoplasms - Neoplastic Process disease
TCMBANKDI017024 Neoplasms; Respiratory Tract Diseases - Neoplastic Process disease
TCMBANKDI017642 Neoplasms Abnormality of the integument; Neoplasm Neoplastic Process disease
TCMBANKDI018353 Chemically-Induced Disorders; Mental Disorders - Sign or Symptom phenotype
TCMBANKDI018731 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome disease
TCMBANKDI019340 - - Disease or Syndrome disease
TCMBANKDI019825 Neoplasms - Neoplastic Process disease
TCMBANKDI020764 Digestive System Diseases Abnormality of the digestive system Disease or Syndrome group
TCMBANKDI022646 Digestive System Diseases; Neoplasms; Endocrine System Diseases Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI022757 Nutritional and Metabolic Diseases - Disease or Syndrome disease
TCMBANKDI024293 Neoplasms Neoplasm Neoplastic Process disease
TCMBANKDI024535 Neoplasms; Respiratory Tract Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI025420 Digestive System Diseases; Neoplasms Abnormality of the digestive system; Neoplasm Neoplastic Process disease
TCMBANKDI026459 Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases Neoplasm; Abnormality of the respiratory system Neoplastic Process disease
TCMBANKDI028471 Respiratory Tract Diseases; Otorhinolaryngologic Diseases - Disease or Syndrome group
TCMBANKDI028799 Eye Diseases - Disease or Syndrome disease
TCMBANKDI029321 Cardiovascular Diseases - Disease or Syndrome group
TCMBANKDI029520 Mental Disorders - Mental or Behavioral Dysfunction group